Home / Stock ratings / GLP-1, Obesity and Biotech Stocks / SRPT
Stock rating
Sarepta Therapeutics,, Inc. (SRPT) Stock Rating & Analysis
As of September 25, 2026, MELANY rates Sarepta Therapeutics,, Inc. 60 out of 100 (Promising). Its highest factor score is earnings track record at 88, and its lowest is business quality at 36.
MELANY ratingRated 2026-09-25SRPT · composite score
Why SRPT scores 60/100
SRPT's 8 factor scores run from 36 to 88, and 4 of them sit above its composite of 60. Here is how SRPT breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
Direction and relative strength of the recent share-price trend.
History of beating or missing estimates, and where estimates are heading.
- Avg EPS beat +21%
What Wall Street price targets and revisions are signalling.
- Institutional net buying +5.1%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
How SRPT compares
As of October 7, 2026, Sarepta Therapeutics,, Inc. is tied for 15th of 20 in GLP-1, Obesity and Biotech Stocks, where the average score is 64.
Key risks for SRPT
- Short interest 29% of float, high volatility risk on news
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Sarepta Therapeutics,, Inc. sits in the Healthcare sector theme, which MELANY currently rates 44/100 for strength. Theme strength feeds SRPT's momentum and catalyst factors above.
SRPT trade plan (Pro)
MELANY has a full position plan for Sarepta Therapeutics,, Inc.: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It is part of Market Eyes Pro, and the first 30 days are free.
How MELANY rates SRPT
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Sarepta Therapeutics,, Inc.'s 60/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about SRPT
Is Sarepta Therapeutics,, Inc. (SRPT) a buy?
As of 2026-09-25, MELANY rated Sarepta Therapeutics,, Inc. Promising with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Sarepta Therapeutics,, Inc.'s MELANY score?
Sarepta Therapeutics,, Inc. (SRPT) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, macro fit.
How is the SRPT stock rating calculated?
MELANY scores SRPT from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Sarepta Therapeutics,, Inc. stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Sarepta Therapeutics,, Inc. (SRPT) Promising with a composite of 60/100 as of 2026-09-25. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the SRPT stock price forecast?
MELANY does not publish price targets or forecasts for SRPT. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Sarepta Therapeutics,, Inc., and re-scores automatically as new price, earnings, and fundamental data arrive.
Is SRPT stock overvalued or undervalued?
MELANY's valuation factor currently reads 82/100 for Sarepta Therapeutics,, Inc., where a higher score means the price looks more attractive on that measure. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives SRPT's read.
What price should I buy SRPT at?
Rather than chasing the current price, MELANY computes a smart entry zone for SRPT: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels are part of Market Eyes Pro, which starts with a 30-day free trial.
What are the risks of buying SRPT stock?
The top risks MELANY currently flags for Sarepta Therapeutics,, Inc.: Short interest 29% of float, high volatility risk on news; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Sarepta Therapeutics,, Inc. a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 36/100 for Sarepta Therapeutics,, Inc., and earnings track record, at 88/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will SRPT stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 50/100 for SRPT right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this SRPT rating?
The rating on this page is a snapshot of MELANY's read as of 2026-09-25. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores SRPT continuously as new price, earnings, and fundamental data arrive, and the current rating is in the app (Pro, free for 30 days).
How this rating works
Market Eyes Live
Every rating graded in public, SRPT included
MELANY scores more than 11,000 U.S. stocks and ETFs, PRISM ranks conviction and APEX writes the plan with one entry zone. Free to start on iOS and the web.